Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...

Eli Lilly (NYSE:LLY) recently announced its plans to invest $27 billion in four new U.S. manufacturing plants over the next five years, creating thousands of jobs. This move comes at a time when ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...

WASHINGTON — Eli Lilly plans to spend $27 billion to build four new drug manufacturing sites in the United States, the company announced Wednesday, at a time when the Trump administration is ...

A major pharmaceutical company that has invested heavily in North Carolina is planning multiple new factories in the U.S. STORY HIGHLIGHTS Eli Lilly plans $27 billion U.S. expansion, will create ...

To help raise awareness for mental health and suicide prevention, "Laps for Lilly,” a 5K run/walk is planned for May 3 beginning at Cottonwood Park on the Mississippi Riverfront, adjacent to the ...

Eli Lilly, a pharmaceutical company, employs more than 12.000 people in Indianapolis and more than 42,000 worldwide © 2025 Fortune Media IP Limited. All Rights ...

It isn't a cheap buy, but given its strong growth prospects, a premium is justifiable. Lilly could obtain approval for a weight loss pill that would unlock even more growth. Investors should never ...